

# Escape from senescence: molecular basis and therapeutic ramifications

Konstantinos Evangelou<sup>1†</sup>, Konstantinos Belogiannis<sup>1†</sup>, Angelos Papaspyropoulos<sup>1,2</sup>, Russell Petty<sup>3</sup> and Vassilis G Gorgoulis<sup>1,2,3,4,5,6\*</sup>

<sup>1</sup> Molecular Carcinogenesis Group, Department of Histology and Embryology, Medical School, National and Kapodistrian University of Athens, Athens, Greece

<sup>2</sup> Biomedical Research Foundation, Academy of Athens, Athens, Greece

<sup>3</sup> Ninewells Hospital and Medical School, University of Dundee, Dundee, UK

<sup>4</sup> Faculty Institute for Cancer Sciences, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK

<sup>5</sup> Center for New Biotechnologies and Precision Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece

<sup>6</sup> Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK

\*Correspondence to: VG Gorgoulis, Molecular Carcinogenesis Group, Department of Histology and Embryology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. E-mail: [vgorg@med.uoa.gr](mailto:vgorg@med.uoa.gr)

†Equal contribution.

## Abstract

Cellular senescence constitutes a stress response mechanism in reaction to a plethora of stimuli. Senescent cells exhibit cell-cycle arrest and altered function. While cell-cycle withdrawal has been perceived as permanent, recent evidence in cancer research introduced the so-called escape-from-senescence concept. In particular, under certain conditions, senescent cells may resume proliferation, acquiring highly aggressive features. As such, they have been associated with tumour relapse, rendering senescence less effective in inhibiting cancer progression. Thus, conventional cancer treatments, incapable of eliminating senescence, may benefit if revisited to include senolytic agents. To this end, it is anticipated that the assessment of the senescence burden in everyday clinical material by pathologists will play a crucial role in the near future, laying the foundation for more personalised approaches. Here, we provide an overview of the investigations that introduced the escape-from-senescence phenomenon, the identified mechanisms, as well as the major implications for pathology and therapy.

© 2023 The Authors. *The Journal of Pathology* published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

**Keywords:** cellular senescence; senescence escape; cancer; pathology; senolytics; therapy

Received 25 April 2023; Revised 16 June 2023; Accepted 19 June 2023

No conflicts of interest were declared.

## What is cellular senescence?

First, the reader is urged to consult the glossary (a glossary of terms is provided in supplementary material, File S1) for definitions and explanations of individual terms used here.

Various cellular states reflect reactions of cells to physiological and harmful insults. A central task in pathology is to define how cells respond when challenged by various stress stimuli preserving tissue and organismal homeostasis [1]. Depending on the features of the stressor, cells balance the decision between life (complete recovery) and death when damage exceeds their repair capacity. Between those two extreme settings, other options linked to cell survival can be adopted. For instance, the cell can remain alive but in an arrested state, preventing the generation of damaged

offspring cells. That arrested cellular state, which ensures homeostasis by restraining damage, is termed cellular senescence [1–3]. Cellular senescence constitutes a fundamental stress response mechanism against a variety of stimuli, external or internal to the cell (Figure 1) [3]. Exposure of cells to such sublethal stress insults mainly results in the accumulation of DNA damage and elicits the DNA damage response (DDR) pathway, which eventually leads to the establishment of cellular senescence [1,3]. In senescent cells, DNA damage manifests itself in the form of DNA breaks, and activation of the DDR pathway is revealed by the formation of persistent DDR foci [1,3–5].

Cellular senescence can be broadly divided into replicative senescence (RS) and stress-induced premature senescence (SIPS) [3,6]. RS was first described by Hayflick in 1961, when proliferation-competent cells were found to cease replication following successive




Figure 1. Schematic representation of a non-exhaustive list of known triggering stimuli (stressors) inducing stress-induced senescence. In turn, replicative senescence is activated upon telomere attrition/dysfunction. Irrespective of the triggering stimulus and the type of the senescent programme initiated, senescent cells exhibit four interconnected hallmark features: cell-cycle arrest, macromolecular damage, altered metabolism, and SASP secretion. ER, endoplasmic reticulum; OIS, oncogene-induced senescence; TIS, therapy-induced senescence.

rounds of cell divisions (Figure 1) [7]. This type of senescence, also referred to as primary senescence, is triggered by progressive telomere shortening per cell division as well as upon telomere modifications and/or dysfunction [2,3,8–10]. However, stress-inducing stimuli were later shown to activate senescence programmes prior to reaching the cellular replicative limit (premature types), which led to the identification of SIPS [1,3,11]. A subset of SIPS is driven by oncogenic stress [oncogene-induced senescence (OIS)], preventing the expansion of incipient cancer cells. Oxidative/metabolic stress along with heat and endoplasmic reticulum stress, infectious agents, and chemoradiotherapeutic modalities are other known triggers of SIPS [3,12–17]. As defined in 2019, senescent cells are characterised by a number of interdependent hallmark features [3]. Senescent cell traits dynamically undergo modifications with time, revealing a multifaceted nature which can be chronologically divided

into ‘early’ and ‘deep’ senescence, depending on the emergence of senescence properties post induction [1,18]. These senescence features include cell-cycle withdrawal, a deregulated metabolic profile, accumulation of macromolecular damage, and acquisition of a unique senescence-associated secretory phenotype (SASP) mainly consisting of pro-inflammatory factors (Figure 1) [3,18–21]. Early senescence pertains to a shift from a transient to a stable cell-cycle arrest where early senescent cells progress to ‘deep’ or ‘full’ senescence once SASP production is established [18].

At the molecular level, it is widely accepted that the majority of senescence triggers convey their signalling towards activation of two cardinal cell-cycle regulatory pathways, the p53/p21<sup>WAF1/Cip1</sup> and p16<sup>INK4A</sup>/RB signalling axes [1]. Interestingly, cytoplasmic lipofuscin accumulation, a hallmark of senescence, reflects both altered metabolic traits and increased macromolecular

damage within the senescent environment [3]. The unique secretory properties of senescent cells include the production of inflammatory cytokines, proteases, and a spectrum of molecules that influence the surrounding microenvironment, in an autocrine and paracrine manner, overall mediating senescent cell elimination by phagocytosis (transient or acute senescence) [3,14,15,19–21].


Intriguingly, senescence seems to behave in a bimodal manner, with SASP action being the key modulating factor. When it occurs transiently (acute), senescence appears beneficial as it contains damage (bright side of senescence). As such, cellular senescence plays an important role in tissue homeostasis even during normal development and adult physiology [19–22]. However, on a long-term basis, senescence exerts its detrimental impact on the onset and outcome of a variety of pathologies and on the ageing process [23–27]. Senescent cells can persist either through the development of immune-evasive mechanisms or due to a decline in the immune system with age (persistent or chronic senescence). Chronic accumulation of senescent cells and excessive SASP are accompanied by progressive detrimental effects at the tissue and organismal level, revealing a ‘dark side’ of senescence [1,3,13,18–21]. Such negative effects involve tissue stem cell niche exhaustion, matrix degradation, and mild chronic inflammation, ultimately impairing tissue functionality and laying the foundation for ageing and age-related disorders [18–22,24,28]. Interestingly, in cancer, which is one of the most common age-related diseases, the induction of OIS as an anti-tumour barrier is well established [3,12,13,29]. An intriguing hypothesis has been proposed in connection with the bimodal nature of SASP. According to this hypothesis, upon initial activation, SASP is enriched in components that exert anti-tumour properties, thereby inducing senescence and/or apoptosis in an autonomous manner. However, with time, SASP becomes enriched in factors that promote, in a bystander manner, tumourigenic activities by suppressing immune cell populations [30].

### Demystifying senescence cell-cycle re-entry

As already noted, cell-cycle arrest plays a central role in the manifestation of senescence, which was considered for many years to occur in an irreversible manner. Nonetheless, as research in the field progressed and new senescence markers were discovered (see the discussion that follows) a question emerged: Is senescence-associated cell-cycle withdrawal reversible? Transitory proliferation states characterised by cell-cycle arrest and re-entry have been identified in the context of premature senescence as well as cell immortalisation following RS *in vitro* [31,32]. Premature senescence is currently related to three distinct phenomena: senescence reversal, senescence bypass, and senescence escape [31–33]. Before delving deeper into the senescence-escape

concept, we clarify the terms and conditions related to cell-cycle re-entry and senescence, which often cause misunderstanding and confusion (see the glossary for further explanation of the terms used). It has been noted that the terms ‘reversal’, ‘bypass’, and ‘escape’ are used interchangeably in the literature to describe either of these cell-cycle re-entry states. A consensus decision should be reached on these definitions to facilitate future research and discussion in this emerging field. *Escape from senescence* is characterised by a reacquisition of replication potency as well as disappearance of lipofuscin aggregates from the cytoplasm. In addition, it is usually preceded by a period of prolonged senescence, whereby a cell is significantly altered at the genomic, transcriptomic, and metabolic levels compared to the pre-senescent state (Figure 2) [33–35]. A phenomenon that is completely irrelevant to senescence is captured by the term *senescence bypass*, during which the senescent state is circumvented upon malignant transformation and the cell cycle is accelerated rather than halted in response to oncogenic stimuli (Figure 2) [36]. Functionally, in senescence escape, gradually acquired genetic alterations are accompanied by aggressive biological cellular traits, such as epithelial-to-mesenchymal transition (EMT), stemness, and drug resistance, while senescence bypass is followed by cellular transformation and the adoption of a malignant phenotype [33,35,37–39]. On the other hand, *senescence reversal* represents a distinct state, where the cell reverts back to its pre-senescent state *shortly* after acquisition of the senescent phenotype (acute/transient senescence) (Figure 2) [40,41]. As such, the structure and function of the cell remain unchanged. The terms ‘pseudo-senescence’, ‘senescence-like’, ‘short-lived’, ‘accelerated’, and ‘uncommitted senescence’ have all been used to describe a senescent state amenable to reversion [42]. With regard to the *in vitro* process of cell immortalisation, this is achieved following replicative stress, leading to short intervals of cellular senescence (M1 and M2 stages) [43,44]. Although immortalisation has been described as the outcome of escape from replicative senescence, those cell-cycle transitory phases are distinct from senescence reversal, bypass, and escape; immortalisation properties are not necessarily tumourigenic (no escape), and the genetic landscape is different (no reversal) [44–49].

From a molecular standpoint, senescence reversal represents a case of acute senescence, which is characterised by low p16<sup>INK4A</sup> levels and a generally unaltered genotype, allowing backtracking to the pre-senescent state [27]. On the other hand, replicative senescence is associated with high p16<sup>INK4A</sup>, which usually also reflects chronic senescence [18–21,24,28]. If a cell has undergone significant genomic, metabolic, and/or epigenetic reorganisation, reversal is not possible. However, cell-cycle re-entry in the form of senescence escape and the emergence of malignant offspring may occur. These transitory cellular state dynamics are not completely understood and require further investigation [27].



**Figure 2.** Overview of role of cellular senescence in cellular and organismal homeostasis through transitory cellular states: escape, reversal, and bypass. The stress signal induces imbalance in the cell's homeostatic equilibrium [disrupted cellular homeostasis (red)], in turn triggering the internal repair machinery as a compensatory mechanism. Depending on the features (hallmarks) of the stressor and the capacity for repair (cellular damage to repair capacity ratio), the affected cell may undergo cell death when the damage is irreparable ( $\gg 1$ ) or completely withstand the inflicted damage achieving homeostasis ( $\ll 1$ ). When the damage is barely withstood ( $\approx 1$ , sublethal), cellular senescence is triggered, and immune cells are chemotactically recruited secondarily to SASP release. When repair is not possible and the damage is critical, the cell dies. Early upon senescence initiation (e.g. low p16<sup>INK4A</sup> levels; see text for more details), reversal to a pre-senescent state is possible after successful damage resolution (green). In the case of lingering unresolved cellular damage, senescent cells can accumulate especially when their clearance is inhibited (red cross), thereby increasing the chances of senescence escape (orange box) and malignant transformation. Moreover, under low p53 and p16<sup>INK4A</sup> levels, the cellular senescence state may be bypassed, leading to a malignant cellular phenotype (yellow box).

The senescence escape phenomenon: mechanistic insights

A number of studies that have emerged in recent decades challenged the dogma of irreversible cell-cycle arrest during senescence and laid the groundwork for the escape-from-senescence concept, a phenomenon with implications in disease progression and therapeutic outcomes (Figure 3, Table 1) [3,33–35]. Although sparse indications for escape from senescence were presented earlier, in the context of therapy-induced senescence (TIS), the first evidence for escape from OIS was presented shortly thereafter (Figure 3, Table 1) [43,78,79]. The oncogenic properties of the replication licensing factors cell division cycle 6 (CDC6) and chromatin licensing and DNA replication factor 1 (CDT1) were elucidated and the escape from the OIS phenomenon was identified through the implementation of an experimental cancer evolution approach [79]. This work, along with earlier pioneering studies, led in 2008 to the proposal of the oncogene-induced DNA damage model for cancer development [12,13,80]. According to this model, activated oncogenes trigger the DDR pathway, which in turn deploys the anti-tumour barriers of apoptosis and senescence, eliminating incipient cancer cells from the earliest stages of cancer development. As DNA damage accumulates, cells' capacity to repair in an error-free manner is exhausted, causing them to shift to an error-prone repair procedure and leading to genomic instability, which eventually breaches anti-tumour barriers and facilitates cancer progression [79]. The model predicted the following aspects: (1) the emergence of genomic instability during cancer development, (2) the manner in which evasion from apoptosis occurs (e.g. frequent TP53 mutations in tumours), (3) activation

of senescence during cancer development, and (4) escape from senescence. As a result, DDR-replication stress, genomic instability, and senescence are now considered hallmarks of cancer [29,81]. Although those predictions were partially supported by various experimental evidence, proof of senescence escape *in vivo* as well as its mechanistic basis were still lacking [12,79,80,82]. An intriguing histopathological observation led us to hypothesise that senescent cells could escape *in vivo*, promoting cancer progression. In particular, in various carcinomas and preneoplastic lesions harbouring p53 defects, we noticed large neoplastic cells paradoxically co-expressing the cell-cycle inhibitor p21<sup>WAF1/Cip1</sup> and the proliferation marker Ki-67 [34]. This observation implied either that proliferating neoplastic cells tolerated increased p21<sup>WAF1/Cip1</sup> levels or that prolonged p21<sup>WAF1/Cip1</sup> activation led to escape from senescence. Based on these findings, it appeared that the traditional tumour suppressor p21<sup>WAF1/Cip1</sup> exerted pro-tumourigenic properties in a p53-deficient setting. Moreover, in this context, a strong tendency of senescent cells to escape was implied, despite overexpression of a potent senescence mediator. We experimentally recapitulated these histopathological observations and indeed observed senescence escape, reflected by the emergence of proliferating cells with aggressive properties and increased tolerance to genotoxic agents [34]. Mechanistically, chronic p21<sup>WAF1/Cip1</sup> upregulation was shown to 'saturate' the CRL4<sup>CDT2</sup> and SCF<sup>Skp2</sup> ubiquitin ligase complexes, restraining turnover of the replication licensing machinery [34]. Constituent replication stress and DDR activation, in a p53-null setting, resulted eventually in a shift from RAD-51-mediated high-fidelity repair processes to RAD-52-modulated low-fidelity repair, fuelling genomic instability (Figure 4) [83].




Figure 3. Timeline of studies that emerged in recent decades dealing with escape-from-senescence concept.



Table 1. Mechanisms of escape from senescence per senescence type and cellular system.

Cell type/cellular system	Mechanism of escape	Reference
<b>Oncogene-induced senescence (OIS)</b>		
Ras-expressing hepatocytes	p19 <sup>ARF</sup> deactivation (spontaneous deficiency and escape)	[50]
HT29 colorectal cell line with absence of p53 and p16	Downregulation (loss) of p21 <sup>WAF/Cip1</sup> and upregulation of Bcl-xL/MCL1 that repress BH3-only proteins such as BIM or PUMA; Aurora-A-PLK1 pathway and CDC25C spindle checkpoint activator are dysregulated (spontaneous escape)	[51]
LS174T cells		
MCF10A mammary epithelial cells	p21 <sup>WAF/Cip1</sup> downregulation (setting: tumourigenesis induced by mammary-targeted Ha-Ras or c-Myc) (artificial escape)	[52]
Colorectal cancer	POU2F2, AP1 upregulation leading to CDKN2A/p16 <sup>INK4a</sup> downregulation	[53]
Human diploid dermal fibroblasts (HSF43) BJ cells (ATCC)	De-repression of hTERT expression in a c-Myc-dependent manner through chromatin rearrangement (spontaneous escape)	[54]
GM21808 MDA-MB-231 cells		
MDA-MB-468 cells		
HCT116 colon cancer cells		
Fibrosarcoma cells (HT-1080)		
Human bronchial epithelial cells	A recurrent chromosomal inversion of BHLHE40 locus, a circadian rhythm-related gene, suffices for driving escape from OIS via subTAD reorganisation	[33]
Colon and breast cancer cells	Upregulated CDK4-EZH2-AP2M1 pathway	[38]
Melanocytes	H3K9me3 histone mark suppression by global H3K9 demethylase activity	[55]
<b>Therapy-induced senescence (TIS)</b>		
HCT116 cells (radiation, PARP inhibitors)	Loss of p16 <sup>INK4a</sup> (spontaneous escape)	[53]
H460 cells (etoposide)	Loss of p16 <sup>INK4a</sup> (spontaneous escape)	[56]
LS174T cells	p21 <sup>WAF/Cip1</sup> downregulation and resultant CD47 and TSP1	[57]
MCF7 cells	downregulation (spontaneous escape)	
Ep-Myc transgenic Bcl-2 overexpressing lymphoma cells	P53 knockdown (spontaneous escape)	[35,39,58]
MCF7 cells	CDK2-mediated c-myc phosphorylation (artificial escape)	[59]
LS174T cells	CyclinD1/CDK4 upregulation (spontaneous escape)	[38]
MCF7 cells		
H1299 human non-small cell lung carcinoma cells	Upregulation of cyclin-dependent kinase Cdc2/Cdk1 (spontaneous escape)	[43]
(-p16/+pRb/deleted p53)		
p53-null NCI-H1299 cells	Cdc2/Cdk1/survivin upregulation (spontaneous escape)	[60]
MCF-7 cells	Enhanced cdc2 (spontaneous escape)	[61]
MCF7 cells	Bystander effect of SASP, non-cell autonomous activation of Notch signalling (spontaneous escape)	[62]
HCT 116 cells	SASP (paracrine spontaneous escape)	[63]
LS174T and HCT116 cells	Inactivation of Noxa and apoptosis inhibition	[64]
LS174T and HCT116 cells (active p53-p21 axis)	Mcl-1 signalling upregulation	[65]
HT29 cells (inactive p53)		
MCF-7 and LS174T cells	1. Overexpression of AGR2 (anterior gradient protein 2) 2. Activation of the mTOR/AKT	[66]
MCF7 cells	Increase glutamate (spontaneous escape)	[67]
A549 cells		
MDA-MB-231 cells	Increased autophagy	[68] (spontaneous escape), [69] (artificial escape)
MCF7 cells		
HCT116 cells		
Colon cancer cells	Redox alterations (increased oxidative stress)	[70]
A549 lung cancer cells	Hypoxia → cyclin B-mediated activity; downregulation of autophagy enhanced escape	[71]
CT116 colon cancer cells		
Ep-Myc transgenic Bcl-2 overexpressing lymphoma cells	1. Gene expression alterations 2. Loss of restrictive epigenetic changes, i.e. Suv39h1 knockdown	[35,39,58]
MCF7 cells	Acquisition of stem cell-like traits	[72] (spontaneous escape), [73]
HCT116 cells		
H1299 (p53 and p16 deficient)	Endoreduplication	[74] (artificial escape), [75] (spontaneous escape), [76] (spontaneous escape)
HCT116 cells		
Hey cells		
SKOV3 cells		
MDA-HGSC-1 cells		
PROb colon cancer cells	DNA endoreduplication and polyploidy (spontaneous escape)	[77]




Figure 4. OIS is characterised by progressively increasing levels of replication stress, genomic damage, and eventually genomic instability. The latter acts as a driving force underlying the escape-from-senescence phenomenon. In TIS, acquisition of a Wnt signalling-related stemness phenotype, as well as routes such as metabolic changes, shifts in cell-cycle regulation, and engagement of different signalling pathways, can break the senescence barrier. The resultant escaped cells harbour aggressive biological features reflected by stemness and EMT.

Overall, our observations implied that genomic instability played a role in escape from senescence, but direct evidence was still lacking.

To address how genomic instability may be the driving force underlying escape from senescence, we recapitulated the entire spectrum of epithelial carcinogenesis, challenging human bronchial cells with the potent oncogene

CDC6 [33,84]. Oncogene-driven genomic instability initially triggered OIS while cells escaped from senescence over time, similar to the aforementioned trajectories. Moreover, escaped cells displayed EMT coupled with a mixed stem cell signature [33,84]. Interestingly, escaped cells exhibited complete resumption of the cell cycle, were invasive, and generated tumours upon

injection into nude mice, thereby recapitulating all major features of cancer cells [33,84]. We identified a number of common genetic aberrations in the escaped cells, ruling out stochasticity. Among those, a recurrent inversion on chromosome 3, which harbours the transcription factor *BHLHE40*, attracted our attention [33]. The basic helix–loop–helix family member E40 (*BHLHE40* also known as *DEC1*) is an essential constituent of the molecular machinery comprising the circadian clock [85–87]. There is substantial evidence linking the circadian clock with the cell-cycle machinery and its disruption has been associated with various pathologies, including cancer [88,89]. The identified inversion was associated with upregulation of *BHLHE40* and an altered expression profile of a plethora of genes that are *BHLHE40* targets, such as mouse double minute 2 homolog (*MDM2*), the main negative regulator of p53 [33,90]. Notably, *BHLHE40* is well known to regulate thousands of genes encompassing many cell-cycle regulators [33,91]. Overall, these findings imply that *BHLHE40* is essential for establishing escaped phenotypes. This hypothesis was functionally tested by artificially inducing inversion in cells, which subsequently displayed the entire spectrum of escape-from-senescence traits [33,92]. Given that inversion is the outcome of replication stress-induced genomic instability, the latter observation confirmed that genomic instability was indeed the driving force underlying escape from oncogene-induced senescence.

In parallel, studies from other groups provided additional evidence for the escape from OIS and TIS phenomenon (Figures 3 and 4, Table 1) [33,35,38,39,43,50–54,56–60,62–73,75–78,93,94]. Two recent investigations stemmed from the same group. In the first, with the use of a well-known TIS lymphoma model, substantial activation of the Wnt signalling pathway and a distinct stem cell signature in senescent cells were observed [35]. The latter feature was introduced as senescence-associated stemness (SAS) [35]. Genetic silencing of key senescence mediators such as p53 led to the generation of senescence escaped cells that displayed significantly elevated tumour-initiating potential reflected by cell proliferation, colony formation capacity, and tumour formation in mice, in line with our findings [33–35]. Characteristically, a rare and spontaneously occurring senescent escape cell population with similar features was also observed in the lymphoma model, without any genetic intervention, verifying our observations on senescence escape [33–35]. The identification of Wnt signalling as the driving force of newly acquired features in TIS lymphomas was not surprising, given that aberrant Wnt signalling has been associated with the renewal of cancer stem cells, proliferation, differentiation, metastasis, and immune surveillance [35,95,96]. Based on those findings, it was suggested that Wnt-induced SAS may be a general mechanism leading to the generation of highly aggressive and malignant tumour-initiating stem cells in response to cancer therapy.

The second investigation dealt with the rescue of chromatin modifications considered essential for the establishment of senescence, thus promoting escape from senescence [3]. In particular, suppression of the H3K9me3 histone marker by global H3K9 demethylase activity was demonstrated to drive escape from Ras-/Braf-induced senescence (OIS) in melanocytes [55]. The escaped cells displayed cell-cycle re-entry, loss of senescence markers and accelerated melanomagenesis. In line with this, high expression of the demethylases lysine-specific demethylase 1 (LSD1) and Jumonji domain 2C (JMJD2C) was common in melanomas and not in senescent nevi or Braf-senescent melanocytes [55]. Of note, inhibition of LSD1 or JMJD2C restored OIS. Overall, these findings indicated the importance of the suppressive H3K9me3 mark not only in the establishment but also in the maintenance of the senescence phenotype [55]. Moreover, co-operation of LSD1 or JMJD2C with activated Ras/Braf leads to cellular transformation and melanomagenesis, revealing the oncogenic properties of aberrant demethylase expression [55]. At the mechanistic level, H3K9 demethylases were shown to promote E2F target gene expression in Ras-driven cells, and their ability to hinder OIS was found to be dependent exclusively on their catalytic function.

Moreover, other routes are reportedly implicated in senescence escape, denoting the multifaceted nature of this phenomenon (Figures 3 and 4, Table 1). The majority seem to converge on genomic instability acquisition, rendering this feature a critical determinant of the senescence escape phenomenon. These avenues include activation of specific signalling pathways, loss of cell-cycle control, perturbation of metabolic processes including oxidative stress/mitochondrial dysfunction, and polyploidy (Figures 3 and 4, Table 1) [38,47,51,58,67,74,97]. Interestingly, activation of CDK4 in chemotherapy-induced senescence was shown to upregulate the enhancer of zeste homolog 2 (EZH2) methylase, a component of the polycomb PRC2 complex. As a result, AP2M1, a factor that plays an essential role in receptor endocytosis, is induced, modulating the surfaceome of senescent cells in the direction of escape [38]. Inactivation of cardinal cell-cycle inhibitors in senescent cells has been proposed as an additional path that leads to senescence escape [47,51,58,97]. Regarding metabolic traits, increased glutamine transporter SLC1A5 and glutamine synthetase have been shown in cancer cells that have escaped from TIS, indicating augmented glutamine metabolism [98]. Additionally, doxorubicin-treated cancer cells were found to display high levels of glutamate following escape from TIS [98]. Polyploidy is a common trait of senescent cells and has been extensively demonstrated in tumour cells following TIS [61,99]. Polyploidy is linked to chromatin reorganisation, stemness, and drug-resistant properties along with enhanced metabolic energy. As such, polyploidy appears to confer on tumour cells the ability to escape from senescence, promoting a more malignant phenotype and avoiding lethality following anti-cancer interventions [42,94,100,101]. Camptothecin-induced senescent H1299



cells are often polyploid and escape spontaneously [100]. Such escape was related to overexpression of CDC2 and its downstream effector survivin, conferring increased viability of the escaped cells [60,78,102]. In addition, CDK1 upregulation has been found to promote polyploidy and subsequent escape from TIS, while there is also evidence for senescence escape mediated by autophagic activation [99,100]. Similarly, polyploid features were also evident in cells escaping from OIS during a cancer evolution experiment [79]. Moreover, senescent cells commonly regarded as multinucleated have been proposed to exert an atypical (asymmetrical) budding mitosis, termed neosis, resulting in the generation of clones with proliferative capacity [103]. Whether mother cells are truly senescent remains unclear.

Overall, introducing the escape-from-senescence phenomenon, particularly in the cancer field, creates the basis for revisiting currently applied treatment modalities that target proliferating cells and renders accurate tracing of senescent cells an issue of paramount importance to pathology and therapy.

### Detecting senescence escape: a challenging task

To detect escape from senescence, we need to identify senescent cells. This is quite easy *in vitro*, given that one of the top senescence markers, SA- $\beta$ -gal, is efficient for cell culture analysis [104]. However, at the *in vivo* level and particularly in archival material, SA- $\beta$ -gal is inefficient [104,105]. This problem was solved with the recently developed GL13 reagent (commercially known as SenTraGor™), which is able to identify senescence in any biological material, including archival material routinely processed in pathology laboratories [106]. GL13 detects lipofuscin, a histological pigment commonly discerned by pathologists. Lipofuscin, the ‘dark matter’ of cells, was initially observed by Adolph Hannover in 1843, but its relationship to a stress state, like senescence, had evaded notice for many years. Moreover, GL13 was used in a multimarker-based algorithm, adopted by the senescence community, for reliable senescence identification [3,107]. Notably, by applying this marker, cellular senescence was detected in a variety of diseases, so *GL13 introduced cellular senescence to pathology*. In particular, GL13 made it possible to identify the first clinical entity harbouring senescent cells, namely Hodgkin lymphoma [37]. This malignancy attracted attention because it exerts a number of morphological and molecular features that are reminiscent of the senescence phenotype. In particular, it is characterised by large neoplastic cells (Reed-Sternberg cells) that are embedded in an inflammatory milieu, exerting robust paracrine functions and expressing markers of senescent cells [p21<sup>WAF1/Cip1</sup>(+)/p16<sup>INK4A</sup>(+)/Ki-67(-) pattern] [108,109]. Notably, lymphomas with high numbers of senescent cells exhibited resistance to chemotherapy, an observation that could be attributed to the pro-tumourigenic properties of prolonged and/or robust

SASP [1,3,109]. The escape-from-senescence phenomenon could also be a mechanism contributing to this outcome (see the next section). Ever since GL13 discovery, the spectrum of pathological entities has been expanded to include benign, preneoplastic, and neoplastic lesions, while senescent cells have also been recognised in various experimental and ageing contexts (Table 2) [37,106,107,110–137]. In particular, in clinical settings, skin pathologies (nevi, seborrheic, and actinic keratoses), lung, pancreatic, urothelial and laryngeal precancerous lesions, various types of carcinomas following treatment, sarcomas, haematological malignancies (Langerhans histiocytosis), and a variety of tissues from aged organs were included (Table 2). Interestingly, while the involvement of senescence in infectious diseases has been hypothesised for many years, during the recent SARS-CoV-2 pandemic it became documented by applying GL13 and the senescence detection algorithm. We demonstrated for the first time in COVID-19 patients that SARS-CoV-2 induces senescence accompanied by SASP [137]. Notably, according to our findings, virally induced senescence constitutes a ‘fertile’ environment for viral mutagenesis [137]. The fate of virally induced senescent cells and whether they might be involved in the ‘long COVID’ lung manifestation, resembling end-stage pulmonary fibrosis, awaits further investigation [137].

Taking the foregoing factors into consideration, apart from the deleterious effects of SASP on the tissue micro-environment, the presence of senescent cells represents a niche of cells potentially susceptible to escape. Given that senescence escape has been associated with adverse effects (aside from SASP), increased incidence of senescence in human lesions reflects a potentially unfavourable predictive marker [33,34,138]. Thus, pathologists should be aware of identifying senescent cells in human lesions in everyday clinical practice. In the near future, as senolytics are anticipated to enter into clinical use, this information will be important in designing the most effective therapeutic strategy, thereby reforming conventional therapies [37,138]. These issues are discussed in the following section.

Regarding the detection of escape *in vivo*, this is a very challenging task, and currently available tools may be of value. Cells that are likely to have undergone escape from senescence in tissues would reside in the vicinity of a senescent cell niche (GL13+/Ki-67- pattern), exhibiting a GL13-/Ki-67+ pattern. Moreover, staining with additional markers such as p21<sup>WAF1/Cip1</sup> and p16<sup>INK4A</sup> (multimarker algorithm) and assessing morphological traits (for instance a spindle shape, which is suggestive of EMT in epithelial cells) could further complement the discrimination of senescent versus escaped cells in the same region. The ‘escaped’ nature of these cells can be further characterised by their isolation via microdissection and analysis by molecular means. Such an approach would lead to the putative identification of common alterations/signatures that are informative regarding the origin of escaped cells from their neighbouring senescent cells. In any case, more sophisticated approaches need

Table 2. Clinical and experimental settings harbouring senescent cells, assessed by GL13 staining.

Tissue/organ/entity	Species	Reference
1. Lymph node (Hodkin lymphomas)	Human	[37]
2. Skin Langerhans histiocytosis		
3. Pancreatic intraepithelial lesions		
<b>Human</b>	Human, C57Bl/6 mice	[106]
1. Liver tissue		
2. Seminal vesicle		
3. Irradiated head and neck carcinomas		
4. Chemotherapy-treated breast tissue		
5. Congenital nevi		
<b>Mouse</b>		
1. K-ras-induced mouse lung adenomas		
2. Bleomycin-induced mouse lungs		
3. Palbociclib treated melanoma xenograft		
<b>Human</b>	Human, mice	[107]
1. Oral fibroma		
2. Bone marrow (megakaryocytes)		
3. Urothelial dysplasia (bladder)		
4. Cartilage and synovium (chronic arthritis)		
<b>Mouse</b>		
<b>Myocardium</b>		
Neuronal tissue	Human	[110]
HeLa cell xenograft tumours	NSG mice	[111]
Thymus gland	Human	[112]
Heart, kidney	Wistar rats	[113]
Pancreatic ductal carcinomas	Human	[114]
Skin (actinic keratosis)	Human, K5-rtTA Mice	[115]
Lung	Human	[116]
Various sarcomas	Human	[117]
Neuronal tissue	Human	[118]
Lung, liver, fatty tissue	Er1F/+ mice	[119]
Skin	Human	[120]
Liver	C57Bl/6 mice	[121]
Breast, lung	Human	[122]
Colon, small intestine	Sv129 and C57Bl/6 mice	[123]
Small intestine	Sv129 mice	[124]
Lung, airway mucosa	Human, golden hamster	[125]
Myocardium	NSG-DR1 mice	[126]
Kidney	C57Bl/6J mice	[127]
Skin (seborrheic keratosis)	Human	[128]
H460 large-cell carcinoma cell line (LCC)	CD1-nude female mice	[129]
Breast	Human	[130]
Brain (frontal cortex, hippocampus)	Human	[131]
Skin	Human 3D organotypic skin epidermis culture	[132]
Lymphoid tissue (lymph node Hodgkin lymphomas)	Human	[133]
Skin (from ventral neck, upper chest region)	C57Bl mice	[134]
Intervertebral disc (cartilage)	Human, Wistar rats	[135]
Lung (NSCL carcinomas ± adjuvant therapy)	Human	[136]
Lung, kidney, liver	Human	[137]

to be developed to tackle this issue. To this end, an attractive strategy is emerging from the generation of patient-derived organoids. This *in vitro* system closely approximates the tissue architecture and physiology *in vivo* and can be exploited to provide information on whether senescence escape took place in a lesion [139,140]. Interestingly, sophisticated multiome means encompassing spatial transcriptomics and single-cell multiomics approaches (10X Genomics platforms) coupled with bioinformatics analysis and artificial intelligence allow simultaneous interrogation of the transcriptome and genome in thousands of individual cells within tissues [141]. As such, these technologies may answer the question of whether cells

with aggressive features originated from niches of senescent cells that eventually underwent escape.

### Therapeutic implications

Currently applied anti-cancer strategies largely rely on interventions (chemo- or radiotherapy) aiming to eliminate proliferating cancer cells [142]. However, such therapies not only fail to remove non-proliferating senescent cells but can also promote senescence (TIS) in cancer cells that survive [143]. The outcome is the emergence of a senescent cancer cell population that exhibits tolerance against traditional therapies, preparing the way

for tumour relapse, metastasis, and unfavourable clinical outcomes, potentially through the acquisition of cancer stemness traits [35]. Of note, escaped cells acquire tolerance against senescence-inducing drugs, a feature reminiscent of tumour recurrence following primary response to therapy in cancer patients [142,143]. In agreement with this, and as mentioned earlier, high levels of OIS in Hodgkin and Reed-Sternberg cells prior to treatment is associated with adverse prognosis [37]. Moreover, based on these facts, senescence has been proposed as a driver of cancer dormancy. The latter is characterised by cells that remain alive in an arrested state and can be reactivated to give rise to tumour relapse and metastatic disease [67,74,144,145]. Interestingly, a cellular state termed quiescence, which is distinct from cellular senescence but shares some common features, has been proposed to play a role in cancer dormancy [3,145]. Quiescent cells are,

like senescent cells, cell-cycle arrested; however, this arrest is reversible and involves another set of molecular pathways (p27<sup>Kip1</sup> activation), while secretory properties and macromolecular damage are absent [3].

For all the foregoing reasons, senescent cells should be removed from adult tissues. Interestingly, senescent cells demonstrate resistance to apoptosis, an important feature that has been exploited in developing drugs for their elimination [3,37,146]. These agents, termed senolytics, kill senescent cells by selectively inducing apoptosis [37,146]. The emergence of senolysis, which targets the anti-apoptotic Bcl-2 family of proteins, has opened new avenues for modifying traditional cancer therapies that need to be further investigated [37,146]. In this context, a combinatorial regime targeting both proliferating and senescent cells in neoplasms was suggested as a promising strategy (Figure 5) [138]. In untreated and treated malignancies, where escape from




Figure 5. Cellular senescence is involved in the earliest (pre-malignant) stages of cancer development (OIS) as well as in tumours following treatment (TIS). Moreover, cancer evolution can be fuelled by the presence of senescent cells either in the tumour or the stromal compartment. Tumour progression and tumour relapse after therapy are related to the escape of cancer cells from their senescent state. Senolytics could be implemented across the timeline of cancer's natural history in conjunction with conventional radio/chemotherapeutic modalities for better clinical benefits. Whether it is safe to eliminate senescent cells in pre-malignant lesions requires thorough investigation and clinical trials.


senescence may facilitate cancer progression, such interventions might prove extremely beneficial. Additional strategies are also intriguing that propose a two-hit synthetic lethality approach in which senescence is initially provoked in cancer cells (TIS) and then senescent cells are selectively eliminated with senolytics [147]. Our awareness of the mechanisms imposing apoptosis tolerance to senescent cells remains limited. Unveiling the mechanistic insights governing this phenomenon is anticipated to boost and expand the therapeutic potential of senolysis and lead to the discovery of more effective tools in the arsenal against cancer. To that end, additional approaches could be tested, based on reagents that induce ferroptosis, a common type of death in senescent cells [148]. Overall, increasing our knowledge of the escape-from-senescence phenomenon carries significant translational potential to redirect currently applied therapies and to develop revolutionary treatments, improving clinical outcomes for cancer patients [138].

### Future perspectives

In this overview of the evidence introducing the concept of senescence escape, we have described how the dogma of permanent cell-cycle withdrawal in senescence has been questioned as attractive translational

implications have arisen. Escape from senescence results in transformed cell offspring and detrimental outcomes. Thus, it is essential to distinguish this phenomenon from other types of cell-cycle re-entry that are either related (escape from RS or senescence reversal) or unrelated (senescence bypass) to the senescence phenotype, also clarifying the existing confusion and misconceptions of the field. To this end, and as research in the field is anticipated to expand our awareness, efforts to establish a consensus in the near future seem to be of utmost value.

Although the body of evidence presented so far suggests that escape from senescence is a dire phenomenon, this may not always be the case. It is not uncommon in biomedicine to observe yin-yang phenomena depending on cellular context [149–153]. Escape from senescence and the immune system may well be such a case. Although evidence remains limited, an indication of this stems from *BHLHE40*. Despite its adverse role in the epithelial compartment, a parallel study showed that a subset of regulatory T cells, termed fragile Tregs, harbouring high levels of *BHLHE40*, suppressed tumourigenesis [33,154,155]. While at first glance this observation appears contentious, it is biologically rational as the organism requires fit immune cells and not senescent or exhausted cells [156,157]. It remains to be shown whether *BHLHE40*-driven programmes may



**Figure 6.** A yin-yang/opposite effect of *BHLHE40* transcription factor among different cell types. *BHLHE40* levels have been associated with contrasting functions between the epithelial/non-immune and immune compartment. Low *BHLHE40* levels are known to favour senescence as an anti-tumour response, while its upregulation may lead to escape towards a tumourigenic phenotype in non-immune cells [158]. In contrast, high *BHLHE40* levels stimulate immune cell fitness and effective responses. Following this concept, downregulation of *BHLHE40* in immune cells might be associated with immune suppression and/or senescence, which warrants investigation.



bypass/escape T-cell senescence, boosting immune cell fitness (Figure 6) [154,158].

On a different front, genomic instability and chromatin reshuffling are common features of senescent cells [3]. In this context, activation of transposable elements (TEs) has been extensively documented [3,159–161]. TEs are DNA sequences able to change their position within the genome [162,163]. We observed a robust upregulation of TE copies during senescence that, however, was drastically reduced upon escape (<https://senequest.net/about>) [164]. Interestingly, some of these increased copies were close to the transcription start site of genes that constitute the SASP phenotype (*CDKN1*, *CCL8*, *CCL13*, *IFNG*, *IL6*) [3,11,18–21]. Given that the expression of SASP factors is reduced in escaped cells, it would be intriguing to delve deeper into the putative TE–SASP expression relationship and elucidate putative mechanistic aspects, thereby further characterising the escape-from-senescence phenomenon.

Last but not least, the improvement or development of novel detection strategies will allow for an even more accurate assessment of the senescent cell burden in human lesions. This is an imperative task, which will enable the design of the most effective therapeutic strategy in the near future, in the context of precision medicine [165]. Moreover, new methodologies that will allow deeper characterisation of the senescence phenotype, including genetic, epigenetic (e.g. chromatin conformation capture, 3C techniques), and transcriptomic (e.g. single-cell or bulk RNAseq) analyses are anticipated to elucidate aspects with therapeutic implications such as the mechanistic basis of resistance to apoptosis. All in all, the clarification of several important concepts related to senescence escape will revolutionise cancer therapy by utilising personalised approaches in a timely fashion, thereby improving patient outcomes.

## Acknowledgements

The authors would like to acknowledge Dr Panagiotis Vasileiou and Dr Aikaterini Polyzou for their constructive contributions to manuscript preparation. We acknowledge support by the National Public Investment Programmes of the Ministry of Development and Investment/General Secretariat for Research and Innovation in the framework of the Flagship Initiative to address SARS-CoV-2 (2020ΣΕ01300001); the European Regional Development Fund of the European Union and Greek National Funds through the Operational Programmes Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH-CREATE-INNOVATE (project codes: T2EDK-02939 and T2EDK-03266); a donation from Sonia Kotopoulos; the Hellenic Foundation for Research and Innovation (HFRI) (grant 3782), and National and Kapodistrian University of Athens- Special Account for Research Grant (SARG) 70/3/8916. AP is co-funded by the Foundation for Education and European Culture (IPEP).

## Author contributions

KB performed the literature search and data analysis. KE, RP and VGG wrote the manuscript. AP, KB and KE prepared the figures. VGG supervised the current work. All authors reviewed and approved the final manuscript.

## References

- Gorgoulis VG, Pefani D-E, Pateras IS, *et al.* Integrating the DNA damage and protein stress responses during cancer development and treatment. *J Pathol* 2018; **246**: 12–40.
- Anderson R, Lagnado A, Maggiorani D, *et al.* Length-independent telomere damage drives post-mitotic cardiomyocyte senescence. *EMBO J* 2019; **38**: e100492.
- Gorgoulis V, Adams PD, Alimonti A, *et al.* Cellular senescence: defining a path forward. *Cell* 2019; **179**: 813–827.
- Di Micco R, Krizhanovsky V, Baker D, *et al.* Cellular senescence in ageing: from mechanisms to therapeutic opportunities. *Nat Rev Mol Cell Biol* 2021; **22**: 75–95.
- Galbiati A, Beauséjour C, d'Adda di Fagnagna F. A novel single-cell method provides direct evidence of persistent DNA damage in senescent cells and aged mammalian tissues. *Aging Cell* 2017; **16**: 422–427.
- Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. *Nat Rev Cancer* 2010; **10**: 51–57.
- Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. *Exp Cell Res* 1961; **25**: 585–621.
- Campisi J. The biology of replicative senescence. *Eur J Cancer* 1997; **33**: 703–709.
- Rossiello F, Jurk D, Passos JF, *et al.* Telomere dysfunction in ageing and age-related diseases. *Nat Cell Biol* 2022; **24**: 135–147.
- Admasu TD, Rae M, Stolzing A. Dissecting primary and secondary senescence to enable new senotherapeutic strategies. *Ageing Res Rev* 2021; **70**: 101412.
- Campisi J, d'Adda di Fagnagna F. Cellular senescence: when bad things happen to good cells. *Nat Rev Mol Cell Biol* 2007; **8**: 729–740.
- Bartkova J, Rezaei N, Liontos M, *et al.* Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. *Nature* 2006; **444**: 633–637.
- Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. *Science* 2008; **319**: 1352–1355.
- Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. *Cell* 2005; **120**: 513–522.
- Ben-Porath I, Weinberg RA. When cells get stressed: an integrative view of cellular senescence. *J Clin Invest* 2004; **113**: 8–13.
- Velichko AK, Petrova NV, Razin SV, *et al.* Mechanism of heat stress-induced cellular senescence elucidates the exclusive vulnerability of early S-phase cells to mild genotoxic stress. *Nucleic Acids Res* 2015; **43**: 6309–6320.
- Blazanin N, Son J, Craig-Lucas AB, *et al.* ER stress and distinct outputs of the IRE1α RNase control proliferation and senescence in response to oncogenic Ras. *Proc Natl Acad Sci* 2017; **114**: 9900–9905.
- van Deursen JM. The role of senescent cells in ageing. *Nature* 2014; **509**: 439–446.
- Muñoz-Espín D, Serrano M. Cellular senescence: from physiology to pathology. *Nat Rev Mol Cell Biol* 2014; **15**: 482–496.
- Muñoz-Espín D, Cañamero M, Maraver A, *et al.* Programmed cell senescence during mammalian embryonic development. *Cell* 2013; **155**: 1104–1118.

21. Storer M, Mas A, Robert-Moreno A, et al. Senescence is a developmental mechanism that contributes to embryonic growth and patterning. *Cell* 2013; **155**: 1119–1130.
22. He S, Sharpless NE. Senescence in health and disease. *Cell* 2017; **169**: 1000–1011.
23. Baker DJ, Wijshake T, Tchkonia T, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. *Nature* 2011; **479**: 232–236.
24. Childs BG, Durik M, Baker DJ, et al. Cellular senescence in aging and age-related disease: from mechanisms to therapy. *Nat Med* 2015; **21**: 1424–1435.
25. Baker DJ, Petersen RC. Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. *J Clin Invest* 2018; **128**: 1208–1216.
26. Finkel T, Serrano M, Blasco MA. The common biology of cancer and ageing. *Nature* 2007; **448**: 767–774.
27. Evangelou K, Vasileiou PVS, Papaspyropoulos A, et al. Cellular senescence and cardiovascular diseases: moving to the “heart” of the problem. *Physiol Rev* 2023; **103**: 609–647.
28. Baker DJ, Sedivy JM. Probing the depths of cellular senescence. *J Cell Biol* 2013; **202**: 11–13.
29. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability—an evolving hallmark of cancer. *Nat Rev Mol Cell Biol* 2010; **11**: 220–228.
30. Alessio N, Acar MB, Squillaro T, et al. Progression of irradiated mesenchymal stromal cells from early to late senescence: changes in SASP composition and anti-tumour properties. *Cell Prolif* 2023; **56**: e13401.
31. Salunkhe S, Mishra SV, Nair J, et al. Nuclear localization of p65 reverses therapy-induced senescence. *J Cell Sci* 2021; **134**: jcs253203.
32. Watanabe Y, Lee SW, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells. *Oncogene* 1997; **14**: 2025–2032.
33. Zampetidis CP, Galanos P, Angelopoulou A, et al. A recurrent chromosomal inversion suffices for driving escape from oncogene-induced senescence via subTAD reorganization. *Mol Cell* 2021; **81**: 4907–4923.e8.
34. Galanos P, Vougas K, Walter D, et al. Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing. *Nat Cell Biol* 2016; **18**: 777–789.
35. Milanovic M, Fan DNY, Belenki D, et al. Senescence-associated reprogramming promotes cancer stemness. *Nature* 2018; **553**: 96–100.
36. De Blander H, Morel A-P, Senaratne AP, et al. Cellular plasticity: a route to senescence exit and tumorigenesis. *Cancer* 2021; **13**: 4561.
37. Myrianthopoulos V, Evangelou K, Vasileiou PVS, et al. Senescence and senotherapeutics: a new field in cancer therapy. *Pharmacol Ther* 2019; **193**: 31–49.
38. Le Duff M, Gouju J, Jonchère B, et al. Regulation of senescence escape by the cdk4-EZH2-AP2M1 pathway in response to chemotherapy. *Cell Death Dis* 2018; **9**: 199.
39. Medema JP. Escape from senescence boosts tumour growth. *Nature* 2018; **553**: 37–38.
40. Beauséjour CM, Krtolica A, Galimi F, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. *EMBO J* 2003; **22**: 4212–4222.
41. Lee S, Schmitt CA. The dynamic nature of senescence in cancer. *Nat Cell Biol* 2019; **21**: 94–101.
42. Saleh T, Bloukh S, Carpenter VJ, et al. Therapy-induced senescence: an “old” friend becomes the enemy. *Cancer* 2020; **12**: 822.
43. Roberson RS, Kussick SJ, Vallieres E, et al. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. *Cancer Res* 2005; **65**: 2795–2803.
44. Romanov SR, Kozakiewicz BK, Holst CR, et al. Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. *Nature* 2001; **409**: 633–637.
45. Reddel RR. The role of senescence and immortalization in carcinogenesis. *Carcinogenesis* 2000; **21**: 477–484.
46. Stampfer MR, Bartley JC. Induction of transformation and continuous cell lines from normal human mammary epithelial cells after exposure to benzo[a]pyrene. *Proc Natl Acad Sci U S A* 1985; **82**: 2394–2398.
47. Brenner AJ, Stampfer MR, Aldaz CM. Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. *Oncogene* 1998; **17**: 199–205.
48. Littlefield JW. Escape from senescence in human keratinocyte cultures. *Exp Gerontol* 1996; **31**: 29–32.
49. Bond JA, Wyllie FS, Wynford-Thomas D. Escape from senescence in human diploid fibroblasts induced directly by mutant p53. *Oncogene* 1994; **9**: 1885–1889.
50. Kang T-W, Yevsa T, Woller N, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. *Nature* 2011; **479**: 547–551.
51. de Carné TS, Guillemain Y, Bélanger A, et al. Escape from p21-mediated oncogene-induced senescence leads to cell dedifferentiation and dependence on anti-apoptotic Bcl-xL and MCL1 proteins. *J Biol Chem* 2011; **286**: 12825–12838.
52. Liu M, Casimiro MC, Wang C, et al. p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. *Proc Natl Acad Sci U S A* 2009; **106**: 19035–19039.
53. Martínez-Zamudio RI, Stefa A, Freitas NLF, et al. Escape from oncogene-induced senescence is controlled by POU2F2 and memorized by chromatin scars. *Cell Genom* 2023; **3**: 100293.
54. Patel PL, Suram A, Mirani N, et al. Derepression of hTERT gene expression promotes escape from oncogene-induced cellular senescence. *Proc Natl Acad Sci U S A* 2016; **113**: E5024–E5033.
55. Yu Y, Schleich K, Yue B, et al. Targeting the senescence-overriding cooperative activity of structurally unrelated H3K9 demethylases in melanoma. *Cancer Cell* 2018; **33**: 322–336.e8.
56. Saleh T, Tyutyunyk-Massey L, Murray GF, et al. Tumor cell escape from therapy-induced senescence. *Biochem Pharmacol* 2019; **162**: 202–212.
57. Guillon J, Petit C, Moreau M, et al. Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment. *Cell Death Dis* 2019; **10**: 199.
58. Prieto LI, Baker DJ. Cellular senescence and the immune system in cancer. *Gerontology* 2019; **65**: 505–512.
59. Pandey K, Park N, Park K-S, et al. Combined CDK2 and CDK4/6 inhibition overcomes palbociclib resistance in breast cancer by enhancing senescence. *Cancer* 2020; **12**: 3566.
60. Wang Q, Wu PC, Roberson RS, et al. Survivin and escaping in therapy-induced cellular senescence. *Int J Cancer* 2011; **128**: 1546–1558.
61. Erenpreisa J, Cragg MS. Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewal. *Cancer Cell Int* 2013; **13**: 92.
62. Zhang N, Ji J, Zhou D, et al. The interaction of the senescent and adjacent breast cancer cells promotes the metastasis of heterogeneous breast cancer cells through notch signaling. *Int J Mol Sci* 2021; **22**: 849.
63. Tato-Costa J, Casimiro S, Pacheco T, et al. Therapy-induced cellular senescence induces epithelial-to-mesenchymal transition and increases invasiveness in rectal cancer. *Clin Colorectal Cancer* 2016; **15**: 170–178.e3.
64. Vétillard A, Jonchère B, Moreau M, et al. Akt inhibition improves irinotecan treatment and prevents cell emergence by switching

- the senescence response to apoptosis. *Oncotarget* 2015; **6**: 43342–43362.
65. Jonchère B, Vétillard A, Toutain B, *et al.* Irinotecan treatment and senescence failure promote the emergence of more transformed and invasive cells that depend on anti-apoptotic Mcl-1. *Oncotarget* 2015; **6**: 409–426.
  66. Maarouf A, Boissard A, Henry C, *et al.* Anterior gradient protein 2 is a marker of tumor aggressiveness in breast cancer and favors chemotherapy-induced senescence escape. *Int J Oncol* 2022; **60**: 5.
  67. Pacifico F, Badolati N, Mellone S, *et al.* Glutamine promotes escape from therapy-induced senescence in tumor cells. *Aging* 2021; **13**: 20962–20991.
  68. Bojko A, Staniak K, Czarnecka-Herok J, *et al.* Improved autophagic flux in escapers from doxorubicin-induced senescence/polyploidy of breast cancer cells. *Int J Mol Sci* 2020; **21**: 6084.
  69. Was H, Barszcz K, Czarnecka J, *et al.* Bafilomycin A1 triggers proliferative potential of senescent cancer cells in vitro and in NOD/SCID mice. *Oncotarget* 2017; **8**: 9303–9322.
  70. Borkowska A, Olszewska A, Skarzynska W, *et al.* High hemin concentration induces escape from senescence of normoxic and hypoxic colon cancer cells. *Cancers* 2022; **14**: 4793.
  71. Olszewska A, Borkowska A, Granica M, *et al.* Escape from cisplatin-induced senescence of hypoxic lung cancer cells can be overcome by hydroxychloroquine. *Front Oncol* 2021; **11**: 738385.
  72. Achuthan S, Santhoshkumar TR, Prabhakar J, *et al.* Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species. *J Biol Chem* 2011; **286**: 37813–37829.
  73. Was H, Czarnecka J, Kominek A, *et al.* Some chemotherapeutics-treated colon cancer cells display a specific phenotype being a combination of stem-like and senescent cell features. *Cancer Biol Ther* 2018; **19**: 63–75.
  74. DeLuca VJ, Saleh T. Insights into the role of senescence in tumor dormancy: mechanisms and applications. *Cancer Metastasis Rev* 2023; **42**: 19–35.
  75. Mosieniak G, Sliwinska MA, Alster O, *et al.* Polyploidy formation in doxorubicin-treated cancer cells can favor escape from senescence. *Neoplasia* 2015; **17**: 882–893.
  76. Niu N, Mercado-Uribe I, Liu J. Dedifferentiation into blastomere-like cancer stem cells via formation of polyploid giant cancer cells. *Oncogene* 2017; **36**: 4887–4900.
  77. Puig P-E, Guilly M-N, Bouchot A, *et al.* Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. *Cell Biol Int* 2008; **32**: 1031–1043.
  78. Elmore LW, Di X, Dumur C, *et al.* Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response. *Clin Cancer Res* 2005; **11**: 2637–2643.
  79. Lontos M, Koutsami M, Sideridou M, *et al.* Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior. *Cancer Res* 2007; **67**: 10899–10909.
  80. Gorgoulis VG, Vassiliou L-VF, Karakaidos P, *et al.* Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. *Nature* 2005; **434**: 907–913.
  81. Hanahan D. Hallmarks of cancer: new dimensions. *Cancer Discov* 2022; **12**: 31–46.
  82. Tsantoulis PK, Kotsinas A, Sfikakis PP, *et al.* Oncogene-induced replication stress preferentially targets common fragile sites in preneoplastic lesions. A genome-wide study. *Oncogene* 2008; **27**: 3256–3264.
  83. Galanos P, Pappas G, Polyzos A, *et al.* Author correction: mutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability. *Genome Biol* 2022; **23**: 107.
  84. Komseli E-S, Pateras IS, Krejsgaard T, *et al.* A prototypical non-malignant epithelial model to study genome dynamics and concurrently monitor micro-RNAs and proteins in situ during oncogene-induced senescence. *BMC Genomics* 2018; **19**: 37.
  85. Fang B, Everett LJ, Jager J, *et al.* Circadian enhancers coordinate multiple phases of rhythmic gene transcription in vivo. *Cell* 2014; **159**: 1140–1152.
  86. Lee Y, Tanggono AS. Potential role of the circadian clock in the regulation of cancer stem cells and cancer therapy. *Int J Mol Sci* 2022; **23**: 14181.
  87. Sato F, Bhawal UK, Yoshimura T, *et al.* DEC1 and DEC2 crosstalk between circadian rhythm and tumor progression. *J Cancer* 2016; **7**: 153–159.
  88. Papagiannakopoulos T, Bauer MR, Davidson SM, *et al.* Circadian rhythm disruption promotes lung tumorigenesis. *Cell Metab* 2016; **24**: 324–331.
  89. Abbott SM, Malkani RG, Zee PC. Circadian disruption and human health: a bidirectional relationship. *Eur J Neurosci* 2020; **51**: 567–583.
  90. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. *Nature* 1997; **387**: 299–303.
  91. Rouillard AD, Gunderson GW, Fernandez NF, *et al.* The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. *Database* 2016; **2016**: baw100.
  92. Angelopoulou A, Paspaspyropoulos A, Papantonis A, *et al.* CRISPR-Cas9-mediated induction of large chromosomal inversions in human bronchial epithelial cells. *STAR Protoc* 2022; **3**: 101257.
  93. Schmitt CA. Senescence-associated reprogramming promotes cancer stemness. *Endocr Abstr* 2018; **56**: S25.2.
  94. Mosieniak G, Sikora E. Polyploidy: the link between senescence and cancer. *Curr Pharm Des* 2010; **16**: 734–740.
  95. Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. *Oncogene* 2017; **36**: 1461–1473.
  96. Clevers H. Wnt/beta-catenin signaling in development and disease. *Cell* 2006; **127**: 469–480.
  97. Walcher L, Kistenmacher A-K, Suo H, *et al.* Cancer stem cells—origins and biomarkers: perspectives for targeted personalized therapies. *Front Immunol* 2020; **11**: 1280.
  98. Pacifico F, Mellone S, D'Incalci M, *et al.* Trabectedin suppresses escape from therapy-induced senescence in tumor cells by interfering with glutamine metabolism. *Biochem Pharmacol* 2022; **202**: 115159.
  99. Dudkowska M, Staniak K, Bojko A, *et al.* The role of autophagy in escaping therapy-induced polyploidy/senescence. *Adv Cancer Res* 2021; **150**: 209–247.
  100. Wang Q, Wu PC, Dong DZ, *et al.* Polyploidy road to therapy-induced cellular senescence and escape. *Int J Cancer* 2013; **132**: 1505–1515.
  101. Saleh T, Carpenter VJ, Bloukh S, *et al.* Targeting tumor cell senescence and polyploidy as potential therapeutic strategies. *Semin Cancer Biol* 2022; **81**: 37–47.
  102. Elmore LW, Rehder CW, Di X, *et al.* Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. *J Biol Chem* 2002; **277**: 35509–35515.
  103. Abbadie C, Pluquet O, Pourtier A. Epithelial cell senescence: an adaptive response to pre-carcinogenic stresses? *Cell Mol Life Sci* 2017; **74**: 4471–4509.
  104. Dimri GP, Lee X, Basile G, *et al.* A biomarker that identifies senescent human cells in culture and in aging skin in vivo. *Proc Natl Acad Sci U S A* 1995; **92**: 9363–9367.
  105. Georgakopoulou EA, Tsimaratou K, Evangelou K, *et al.* Specific lipofuscin staining as a novel biomarker to detect replicative and stress-induced senescence. A method applicable in cryo-preserved and archival tissues. *Aging* 2013; **5**: 37–50.
  106. Evangelou K, Lougiakis N, Rizou SV, *et al.* Robust, universal biomarker assay to detect senescent cells in biological specimens. *Aging Cell* 2017; **16**: 192–197.
  107. Kohli J, Wang B, Brandenburg SM, *et al.* Algorithmic assessment of cellular senescence in experimental and clinical specimens. *Nat Protoc* 2021; **16**: 2471–2498.



108. Küppers R, Engert A, Hansmann M-L. Hodgkin lymphoma. *J Clin Invest* 2012; **122**: 3439–3447.
109. Gopas J, Stern E, Zurgil U, et al. Reed-Sternberg cells in Hodgkin's lymphoma present features of cellular senescence. *Cell Death Dis* 2016; **7**: e2457.
110. Kritsilis M, Rizou SV, Koutsoudaki PN, et al. Ageing, cellular senescence and neurodegenerative disease. *Int J Mol Sci* 2018; **19**: 2937.
111. Beauvarlet J, Bensadoun P, Darbo E, et al. Modulation of the ATM/autophagy pathway by a G-quadruplex ligand tips the balance between senescence and apoptosis in cancer cells. *Nucleic Acids Res* 2019; **47**: 2739–2756.
112. Barbouti A, Evangelou K, Pateras IS, et al. In situ evidence of cellular senescence in thymic epithelial cells (TECs) during human thymic involution. *Mech Ageing Dev* 2019; **177**: 88–90.
113. Karageorgiadi DM, Tsilimigras DI, Selemenakis P, et al. Conditioning attenuates kidney and heart injury in rats following transient suprarenal occlusion of the abdominal aorta. *Sci Rep* 2020; **10**: 5040.
114. Papalampros A, Vailas M, Ntostoglou K, et al. Unique spatial immune profiling in pancreatic ductal adenocarcinoma with enrichment of exhausted and senescent T cells and diffused CD47-SIRP $\alpha$  expression. *Cancer* 2020; **12**: 1825.
115. Azazmeh N, Assouline B, Winter E, et al. Chronic expression of p16<sup>INK4a</sup> in the epidermis induces Wnt-mediated hyperplasia and promotes tumor initiation. *Nat Commun* 2020; **11**: 1–13.
116. Giatromanolaki A, Kouroupi M, Balaska K, et al. A novel lipofuscin-detecting marker of senescence relates with hypoxia, dysregulated autophagy and with poor prognosis in non-small-cell-lung cancer. *In Vivo* 2020; **34**: 3187–3193.
117. Giatromanolaki A, Kouroupi M, Balaska K, et al. Immunohistochemical detection of senescence markers in human sarcomas. *Pathol Res Pract* 2020; **216**: 152800.
118. Papadopoulos D, Magliozzi R, Mitsikostas DD, et al. Aging, cellular senescence, and progressive multiple sclerosis. *Front Cell Neurosci* 2020; **14**: 178.
119. Goulielmaki E, Ioannidou A, Tsekrekou M, et al. Tissue-infiltrating macrophages mediate an exosome-based metabolic reprogramming upon DNA damage. *Nat Commun* 2020; **11**: 42.
120. Hasegawa T, Oka T, Son HG, et al. Cytotoxic CD4<sup>+</sup> T cells eliminate senescent cells by targeting cytomegalovirus antigen. *Cell* 2023; **186**: 1417–1431.e20.
121. Moustakas II, Katsarou A, Legaki A-I, et al. Hepatic senescence accompanies the development of NAFLD in non-aged mice independently of obesity. *Int J Mol Sci* 2021; **22**: 3446.
122. Venkatesan S, Angelova M, Puttick C, et al. Induction of APOBEC3 exacerbates DNA replication stress and chromosomal instability in early breast and lung cancer evolution. *Cancer Discov* 2021; **11**: 2456–2473.
123. Martin OCB, Bergonzini A, Lopez Chiloeches M, et al. Influence of the microenvironment on modulation of the host response by typhoid toxin. *Cell Rep* 2021; **35**: 108931.
124. Mathiasen SL, Gall-Mas L, Pateras IS, et al. Bacterial genotoxins induce T cell senescence. *Cell Rep* 2021; **35**: 109220.
125. Lee S, Yu Y, Trimpert J, et al. Virus-induced senescence is a driver and therapeutic target in COVID-19. *Nature* 2021; **599**: 283–289.
126. Delgado M, Heinrichs M, Hapke N, et al. Terminally differentiated CD4<sup>+</sup> T cells promote myocardial inflammaging. *Front Immunol* 2021; **12**: 584538.
127. van Vliet T, Varela-Eirin M, Wang B, et al. Physiological hypoxia restrains the senescence-associated secretory phenotype via AMPK-mediated mTOR suppression. *Mol Cell* 2021; **81**: 2041–2052.e6.
128. Georgakopoulou EA, Valsamidi C, Veroutis D, et al. The bright and dark side of skin senescence. Could skin rejuvenation anti-senescence interventions become a “bright” new strategy for the prevention of age-related skin pathologies? *Mech Ageing Dev* 2021; **193**: 111409.
129. Gabasa M, Radisky ES, Ikemori R, et al. MMP1 drives tumor progression in large cell carcinoma of the lung through fibroblast senescence. *Cancer Lett* 2021; **507**: 1–12.
130. Sirinian C, Peroukidis S, Kriegsmann K, et al. Cellular senescence in normal mammary gland and breast cancer. Implications for cancer therapy. *Genes* 2022; **13**: 994.
131. Salech F, SanMartín CD, Concha-Cerda J, et al. Senescence markers in peripheral blood mononuclear cells in amnesic mild cognitive impairment and Alzheimer's disease. *Int J Mol Sci* 2022; **23**: 9387.
132. Tan CYR, Tan CL, Chin T, et al. Nicotinamide prevents UVB- and oxidative stress- induced photoaging in human primary keratinocytes. *J Invest Dermatol* 2022; **142**: 1670–1681.e12.
133. Kyriazopoulou L, Karpathiou G, Hatzimichael E, et al. Autophagy and cellular senescence in classical Hodgkin lymphoma. *Pathol Res Pract* 2022; **236**: 153964.
134. Paldor M, Levkovitch-Siany O, Eidelstein D, et al. Single-cell transcriptomics reveals a senescence-associated IL-6/CCR6 axis driving radiodermatitis. *EMBO Mol Med* 2022; **14**: e15653.
135. Veroutis D, Kouroumalis A, Lagopati N, et al. Evaluation of senescent cells in intervertebral discs by lipofuscin staining. *Mech Ageing Dev* 2021; **199**: 111564.
136. Domen A, Deben C, De Pauw I, et al. Prognostic implications of cellular senescence in resected non-small cell lung cancer. *Transl Lung Cancer Res* 2022; **11**: 1526–1539.
137. Evangelou K, Veroutis D, Paschalaki K, et al. Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis. *Eur Respir J* 2022; **60**: 2102951.
138. Zampetidis CP, Papantonis A, Gorgoulis VG. Escape from senescence: revisiting cancer therapeutic strategies. *Mol Cell Oncol* 2022; **9**: 2030158.
139. Liu L, Yu L, Li Z, et al. Patient-derived organoid (PDO) platforms to facilitate clinical decision making. *J Transl Med* 2021; **19**: 40.
140. Yang H, Sun L, Liu M, et al. Patient-derived organoids: a promising model for personalized cancer treatment. *Gastroenterol Rep* 2018; **6**: 243–245.
141. Danielski K. Guidance on processing the 10x genomics single cell gene expression assay. *Methods Mol Biol* 2023; **2584**: 1–28.
142. Tannock IF. Conventional cancer therapy: promise broken or promise delayed? *Lancet* 1998; **351**: SII9–SII16.
143. Prasanna PG, Citrin DE, Hildesheim J, et al. Therapy-induced senescence: opportunities to improve anticancer therapy. *J Natl Cancer Inst* 2021; **113**: 1285–1298.
144. Phan TG, Croucher PI. The dormant cancer cell life cycle. *Nat Rev Cancer* 2020; **20**: 398–411.
145. Truskowski K, Amend SR, Pienta KJ. Dormant cancer cells: programmed quiescence, senescence, or both? *Cancer Metastasis Rev* 2023; **42**: 37–47.
146. Zhu Y, Tchkonina T, Fuhrmann-Stroissnigg H, et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. *Ageing Cell* 2016; **15**: 428–435.
147. Birch J, Gil J. Senescence and the SASP: many therapeutic avenues. *Genes Dev* 2020; **34**: 1565–1576.
148. Coradduzza D, Congiargiu A, Chen Z, et al. Ferroptosis and senescence: a systematic review. *Int J Mol Sci* 2023; **24**: 3658.
149. Maiese K. Yin yang: a balancing act for oxidative stress. *Oxid Med Cell Longev* 2010; **3**: 227.
150. So AY-L, Zhao JL, Baltimore D. The yin and yang of microRNAs: leukemia and immunity. *Immunol Rev* 2013; **253**: 129–145.
151. Carrega P, Campana S, Bonaccorsi I, et al. The yin and yang of innate lymphoid cells in cancer. *Immunol Lett* 2016; **179**: 29–35.
152. Borys SM, Bag AK, Brossay L, et al. The yin and yang of targeting KLRG1<sup>+</sup> Tregs and effector cells. *Front Immunol* 2022; **13**: 894508.



153. Evangelou K, Tsantoulis PK, Kotsinas A, *et al.* The opposing roles of E2Fs in cancer. Chapter 13. In *Control of Cellular Physiology by Transcription Factors E2F*. Research Signpost: Trivandrum, India, 2008; 223–241.
154. Hatzioannou A, Banos A, Sakelaropoulos T, *et al.* An intrinsic role of IL-33 in T<sub>reg</sub> cell-mediated tumor immunoevasion. *Nat Immunol* 2020; **21**: 75–85.
155. Overacre-Delgoffe AE, Vignali DAA. Treg fragility: a prerequisite for effective antitumor immunity? *Cancer Immunol Res* 2018; **6**: 882–887.
156. Blank CU, Haining WN, Held W, *et al.* Defining ‘T cell exhaustion’. *Nat Rev Immunol* 2019; **19**: 665–674.
157. Chow A, Perica K, Klebanoff CA, *et al.* Clinical implications of T cell exhaustion for cancer immunotherapy. *Nat Rev Clin Oncol* 2022; **19**: 775–790.
158. Li W, Qiu S, Chen J, *et al.* Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy. *Immunity* 2020; **53**: 456–470.e6.
159. Wang J, Geesman GJ, Hostikka SL, *et al.* Inhibition of activated pericentromeric SINE/Alu repeat transcription in senescent human adult stem cells reinstates self-renewal. *Cell Cycle* 2011; **10**: 3016–3030.
160. Saul D, Kosinsky RL, Atkinson EJ, *et al.* A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues. *Nat Commun* 2022; **13**: 4827.
161. Capone S, Colombo AR, Johnson BK, *et al.* Methylome of human senescent hematopoietic progenitors. *Exp Hematol Oncol* 2018; **7**: 32.
162. Hayward A, Gilbert C. Transposable elements. *Curr Biol* 2022; **32**: R904–R909.
163. Bourque G, Burns KH, Gehring M, *et al.* Ten things you should know about transposable elements. *Genome Biol* 2018; **19**: 199.
164. SeneQuest. [Accessed 31 October 2019]. Available from: <http://senequest.net>.
165. Joyner MJ, Paneth N. Promises, promises, and precision medicine. *J Clin Invest* 2019; **129**: 946–948.

## SUPPLEMENTARY MATERIAL ONLINE

File S1. Glossary of terms